Free Trial
→ Warning: “DOGE Collapse” imminent (From Altimetry) (Ad) Buy PLSE Stock  Free PLSE Stock Alerts

Pulse Biosciences (PLSE) Financials

Pulse Biosciences logo
$17.07 -0.12 (-0.69%)
As of 11:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Pulse Biosciences

Annual Income Statements for Pulse Biosciences

This table shows Pulse Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -2.81 -9.52 -26 -38 -47 -50 -64 -59 -42 -54
Consolidated Net Income / (Loss)		 -2.81 -9.52 -26 -38 -47 -50 -64 -59 -42 -54
Net Income / (Loss) Continuing Operations		 -2.81 -9.52 -26 -38 -47 -50 -64 -59 -42 -54
Total Pre-Tax Income 		-4.47 -9.52 -26 -38 -47 -50 -64 -59 -42 -54
Total Operating Income		 -4.47 -9.52 -26 -38 -48 -50 -63 -58 -44 -56
Total Gross Profit		 0.00 0.07 0.25 0.45 0.00 0.00 -0.55 -11 0.00 0.00
Total Revenue		 0.00 0.07 0.25 0.45 0.00 0.00 1.42 0.70 0.00 0.00
Operating Revenue		 0.00 0.07 0.25 0.45 - 0.00 1.42 0.70 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 1.97 12 0.00 0.00
Total Operating Expenses		 4.47 9.59 26 38 48 50 62 47 44 56
Selling, General & Admin Expense		 1.62 3.42 16 20 17 16 19 14 16 24
Research & Development Expense		 2.18 5.51 9.65 17 25 26 29 21 28 32
Total Other Income / (Expense), net		 0.00 0.00 0.00 0.00 0.98 0.11 -0.65 -0.45 1.36 2.67
Interest & Investment Income		 0.00 - - - 0.98 0.11 -0.65 -0.45 1.36 2.67
Income Tax Expense		 -1.66 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Basic Earnings per Share		 ($0.37) ($0.86) ($1.73) ($2.20) ($2.26) ($2.14) ($2.28) ($1.72) ($0.85) ($0.92)
Weighted Average Basic Shares Outstanding		 7.57M 11.01M 14.75M 17.08M 20.75M 23.25M 27.96M 33.94M 49.74M 58.40M
Weighted Average Diluted Shares Outstanding		 7.57M 11.01M 14.75M 17.08M 20.75M 23.25M 27.96M 37.59M 55.23M 67.27M
Weighted Average Basic & Diluted Shares Outstanding		 7.57M 11.01M 14.75M 17.08M 20.75M 23.25M 27.96M 37.59M 55.23M 67.27M

Quarterly Income Statements for Pulse Biosciences

This table shows Pulse Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -18 -9.20 -9.80 -9.91 -11 -12 -10 -11 -13 -19
Consolidated Net Income / (Loss)		 -18 -9.20 -9.80 -9.91 -11 -12 -10 -11 -13 -19
Net Income / (Loss) Continuing Operations		 -18 -9.20 -9.80 -9.91 -11 -12 -10 -11 -13 -19
Total Pre-Tax Income 		-18 -9.20 -9.80 -9.91 -11 -12 -10 -11 -13 -19
Total Operating Income		 -18 -8.75 -9.56 -10 -11 -13 -11 -12 -14 -20
Total Operating Expenses		 9.63 7.45 9.56 10 11 13 11 12 14 20
Selling, General & Admin Expense		 3.09 2.58 3.73 3.53 3.78 4.73 3.87 4.50 5.95 9.60
Research & Development Expense		 4.52 4.10 5.83 6.70 7.47 7.80 6.74 7.23 7.70 11
Total Other Income / (Expense), net		 -0.01 -0.45 -0.24 0.32 0.69 0.60 0.48 0.34 0.98 0.88
Interest & Investment Income		 -0.01 -0.45 -0.24 0.32 0.69 0.60 0.48 0.34 0.98 0.88
Basic Earnings per Share		 ($0.49) ($0.21) ($0.26) ($0.22) ($0.19) ($0.18) ($0.18) ($0.20) ($0.21) ($0.33)
Weighted Average Basic Shares Outstanding		 37.16M 33.94M 37.39M 46.09M 56.87M 49.74M 55.17M 57.18M 61.07M 58.40M
Weighted Average Diluted Shares Outstanding		 37.23M 37.59M 37.64M 54.90M 54.99M 55.23M 55.23M 61.29M 61.52M 67.27M
Weighted Average Basic & Diluted Shares Outstanding		 37.23M 37.59M 37.64M 54.90M 54.99M 55.23M 55.23M 61.29M 61.52M 67.27M

Annual Cash Flow Statements for Pulse Biosciences

This table details how cash moves in and out of Pulse Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -3.40 -1.52 1.30 48 -44 5.56 16 33 -17 74
Net Cash From Operating Activities		 -3.32 -8.05 -11 -24 -34 -35 -54 -47 -33 -36
Net Cash From Continuing Operating Activities		 -3.32 -8.05 -11 -24 -34 -35 -54 -47 -33 -36
Net Income / (Loss) Continuing Operations		 -2.81 -9.52 -26 -38 -47 -50 -64 -59 -42 -54
Consolidated Net Income / (Loss)		 -2.81 -9.52 -26 -38 -47 -50 -64 -59 -42 -54
Depreciation Expense		 0.05 0.09 0.34 0.65 0.49 0.43 0.48 0.69 0.54 0.51
Amortization Expense		 0.67 0.67 0.69 0.53 0.15 0.67 0.68 0.67 0.67 0.67
Non-Cash Adjustments To Reconcile Net Income		 0.40 0.87 13 12 11 10 15 15 6.44 13
Changes in Operating Assets and Liabilities, net		 -1.63 -0.17 0.41 0.11 0.79 2.89 -6.31 -4.63 1.53 2.63
Net Cash From Investing Activities		 -0.09 -14 -23 26 -10 10 7.56 -0.40 -0.12 -0.13
Net Cash From Continuing Investing Activities		 -0.09 -14 -23 26 -10 10 7.56 -0.40 -0.12 -0.13
Purchase of Property, Plant & Equipment		 -0.09 -0.06 -2.55 -0.28 -0.61 -0.44 -0.44 -0.40 -0.12 -0.13
Net Cash From Financing Activities		 0.00 21 35 45 0.08 31 63 80 16 110
Net Cash From Continuing Financing Activities		 0.00 21 35 45 0.08 31 63 80 16 110
Repayment of Debt		 - - - - 0.00 0.00 -1.53 -0.44 -0.01 0.00
Repurchase of Common Equity		 - - - - - - - - 0.00 -0.28
Issuance of Common Equity		 0.00 21 35 45 0.42 30 58 15 0.40 60
Other Financing Activities, net		 0.00 - 0.54 0.38 -0.34 0.96 4.77 0.03 16 50

Quarterly Cash Flow Statements for Pulse Biosciences

This table details how cash moves in and out of Pulse Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 54 -8.02 -7.04 4.65 -8.36 -6.02 -9.48 -8.69 53 39
Net Cash From Operating Activities		 -11 -7.97 -6.57 -9.20 -10 -6.78 -9.78 -8.40 -9.02 -9.14
Net Cash From Continuing Operating Activities		 -11 -7.97 -6.57 -9.20 -10 -6.78 -9.78 -8.40 -9.02 -9.14
Net Income / (Loss) Continuing Operations		 -18 -9.20 -9.80 -9.91 -11 -12 -10 -11 -13 -19
Consolidated Net Income / (Loss)		 -18 -9.20 -9.80 -9.91 -11 -12 -10 -11 -13 -19
Depreciation Expense		 0.17 0.17 0.14 0.14 0.13 0.14 0.13 0.13 0.13 0.12
Amortization Expense		 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17
Non-Cash Adjustments To Reconcile Net Income		 7.80 2.90 1.89 1.62 -0.40 3.33 1.73 2.02 2.94 6.76
Changes in Operating Assets and Liabilities, net		 -0.73 -2.00 1.04 -1.21 0.18 1.52 -1.67 0.67 0.43 3.20
Net Cash From Investing Activities		 -0.06 -0.04 -0.04 -0.02 -0.02 -0.04 -0.01 -0.03 -0.04 -0.05
Net Cash From Continuing Investing Activities		 -0.06 -0.04 -0.04 -0.02 -0.02 -0.04 -0.01 -0.03 -0.04 -0.05
Purchase of Property, Plant & Equipment		 -0.06 -0.04 -0.04 -0.02 -0.02 -0.04 -0.01 -0.03 -0.04 -0.05
Net Cash From Financing Activities		 65 -0.02 -0.43 14 2.15 0.80 0.31 -0.27 62 48
Net Cash From Continuing Financing Activities		 65 -0.02 -0.43 14 2.17 0.80 0.31 -0.27 62 48
Repurchase of Common Equity		 - - - - - - - - 0.06 -0.06
Other Financing Activities, net		 0.02 0.01 0.19 15 0.31 0.80 0.01 0.01 2.01 48

Annual Balance Sheets for Pulse Biosciences

This table presents Pulse Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 14 26 50 71 42 41 59 78 59 132
Total Current Assets		 4.00 17 38 60 26 22 45 62 45 119
Cash & Equivalents		 3.61 2.09 3.39 51 6.90 12 44 61 44 118
Prepaid Expenses		 0.04 0.27 0.41 0.78 1.01 1.86 0.96 1.01 0.96 1.41
Plant, Property, & Equipment, net		 0.33 0.32 2.57 2.17 2.57 2.48 1.53 1.96 1.53 1.16
Total Noncurrent Assets		 10.00 9.33 8.77 8.11 13 16 12 14 12 12
Goodwill		 2.79 2.79 2.79 2.79 2.79 2.79 2.79 2.79 2.79 2.79
Intangible Assets		 7.21 6.54 5.88 5.21 4.55 3.88 1.89 2.55 1.89 1.22
Other Noncurrent Operating Assets		 - 0.00 0.10 0.10 5.61 9.80 7.62 8.43 7.62 7.84
Total Liabilities & Shareholders' Equity		 14 26 50 71 42 41 59 78 59 132
Total Liabilities		 0.66 1.02 3.83 4.31 11 18 15 80 15 18
Total Current Liabilities		 0.66 1.02 2.21 3.11 4.46 7.59 6.71 5.98 6.71 10
Accounts Payable		 0.26 0.27 0.78 1.27 1.96 1.72 1.84 1.57 1.84 1.67
Accrued Expenses		 0.40 0.75 1.03 1.42 2.50 5.33 3.81 2.60 3.81 7.03
Other Current Liabilities		 - - - - 0.00 0.54 1.06 0.90 1.06 1.36
Total Noncurrent Liabilities		 0.00 0.00 1.61 1.20 6.72 11 8.09 74 8.09 7.54
Other Noncurrent Operating Liabilities		 - - - - 6.72 11 8.09 9.14 8.09 7.54
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 14 25 46 66 31 23 44 -2.25 44 115
Total Preferred & Common Equity		 14 25 46 66 31 23 44 -2.25 44 115
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 14 25 46 66 31 23 44 -2.25 44 115
Common Stock		 17 38 84 142 153 195 381 292 381 505
Retained Earnings		 -3.09 -13 -38 -76 -123 -173 -337 -295 -337 -391
Accumulated Other Comprehensive Income / (Loss)		 - -0.01 -0.05 -0.00 0.00 -0.00 0.00 0.00 0.00 0.00

Quarterly Balance Sheets for Pulse Biosciences

This table presents Pulse Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 88 70 75 66 49 40 93
Total Current Assets		 71 55 60 52 36 27 80
Cash & Equivalents		 69 54 59 50 35 26 79
Prepaid Expenses		 1.24 0.85 1.21 1.24 0.96 1.04 1.38
Plant, Property, & Equipment, net		 2.29 1.87 1.76 1.65 1.40 1.31 1.22
Total Noncurrent Assets		 14 13 13 13 12 12 11
Goodwill		 2.79 2.79 2.79 2.79 2.79 2.79 2.79
Intangible Assets		 2.72 2.38 2.22 2.05 1.72 1.55 1.39
Other Noncurrent Operating Assets		 8.62 8.23 8.04 7.83 7.41 7.53 7.23
Total Liabilities & Shareholders' Equity		 88 70 75 66 49 40 93
Total Liabilities		 81 81 14 14 13 13 14
Total Current Liabilities		 7.00 6.99 5.61 5.43 5.08 5.96 6.74
Accounts Payable		 2.02 2.16 1.79 1.41 1.71 1.64 1.73
Accrued Expenses		 3.98 3.09 2.84 3.00 2.27 3.18 3.82
Other Current Liabilities		 0.86 0.94 0.98 1.02 1.10 1.15 1.19
Total Noncurrent Liabilities		 74 74 8.64 8.37 7.80 7.50 7.17
Other Noncurrent Operating Liabilities		 9.38 8.90 8.64 8.37 7.80 7.50 7.17
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 6.19 -11 61 52 36 27 79
Total Preferred & Common Equity		 6.19 -11 61 52 36 27 79
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 6.19 -11 61 52 36 27 79
Common Stock		 292 294 375 377 383 385 450
Retained Earnings		 -286 -305 -314 -325 -347 -358 -371
Accumulated Other Comprehensive Income / (Loss)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Annual Metrics and Ratios for Pulse Biosciences

This table displays calculated financial ratios and metrics derived from Pulse Biosciences' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 263.24% 80.57% -100.00% 0.00% 0.00% -50.63% -100.00% 0.00%
EBITDA Growth		 0.00% -133.40% -180.30% -48.23% -30.08% -3.28% -26.58% 8.33% 25.28% -30.00%
EBIT Growth		 0.00% -113.03% -168.62% -46.85% -27.72% -4.19% -26.12% 7.87% 24.95% -29.11%
NOPAT Growth		 0.00% -113.03% -168.62% -46.85% -27.72% -4.19% -26.12% 7.87% 24.95% -29.11%
Net Income Growth		 0.00% -238.60% -168.62% -46.85% -25.11% -6.13% -27.70% 8.10% 27.85% -26.95%
EPS Growth		 0.00% -132.43% -101.16% -27.17% -2.73% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 0.00% -142.72% -37.71% -115.53% -43.06% -3.45% -52.97% 13.10% 29.72% -9.99%
Free Cash Flow Firm Growth		 0.00% 0.00% -207.27% -48.38% -28.08% 0.31% -53.49% 27.53% 21.57% -29.47%
Invested Capital Growth		 0.00% -11.49% -10.97% -14.82% -20.92% -54.69% 210.54% -66.32% -100.20% -63,420.00%
Revenue Q/Q Growth		 0.00% 100.00% 61.44% 1.59% -100.00% 100.00% 185.89% -54.93% 100.00% 0.00%
EBITDA Q/Q Growth		 0.00% -16.92% -30.81% -0.72% -14.27% 2.06% -2.61% 10.57% -9.91% -16.36%
EBIT Q/Q Growth		 0.00% -15.45% -29.96% -0.67% -13.81% 1.84% -2.57% 10.30% -9.52% -15.92%
NOPAT Q/Q Growth		 0.00% -15.45% -29.96% -0.67% -13.81% 1.84% -2.57% 10.30% -9.52% -15.92%
Net Income Q/Q Growth		 0.00% -23.19% -29.96% -0.67% -11.47% 0.08% -2.69% 9.61% -6.93% -16.15%
EPS Q/Q Growth		 0.00% -8.86% -25.36% 1.79% -6.60% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% -13.99% -17.42% -10.88% -9.23% -0.17% -6.79% 9.14% 3.46% -6.95%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -35.20% 0.63% -11.17% 0.65% -6.11% 12.92% -1.76% -12.07%
Invested Capital Q/Q Growth		 0.00% -2.70% 0.41% -4.28% -17.65% -22.42% 15.89% 19.06% -100.28% -3,340.82%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 100.00% 100.00% 100.00% 0.00% 0.00% -38.79% -1,606.29% 0.00% 0.00%
EBITDA Margin		 0.00% -12,875.00% -9,935.22% -8,155.83% 0.00% 0.00% -4,362.13% -8,100.29% 0.00% 0.00%
Operating Margin		 0.00% -13,997.06% -10,351.01% -8,418.16% 0.00% 0.00% -4,443.86% -8,293.86% 0.00% 0.00%
EBIT Margin		 0.00% -13,997.06% -10,351.01% -8,418.16% 0.00% 0.00% -4,443.86% -8,293.86% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% -13,997.06% -10,351.01% -8,418.16% 0.00% 0.00% -4,489.42% -8,357.86% 0.00% 0.00%
Tax Burden Percent		 62.91% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 97.95% 99.77% 101.03% 100.77% 96.87% 95.25%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -70.27% -212.69% -358.13% 0.00% 0.00% -888.33% -809.40% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -41.72% -184.53% -335.06% 0.00% 0.00% -807.96% -656.71% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 21.42% 140.97% 291.28% 0.00% 0.00% 671.00% 459.51% 0.00% 0.00%
Return on Equity (ROE)		 -20.57% -48.86% -71.72% -66.85% -96.78% -185.90% -217.33% -349.89% -200.47% -67.31%
Cash Return on Invested Capital (CROIC)		 0.00% -58.08% -201.08% -342.12% -531.94% -826.39% -990.89% -710.18% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -46.84% -67.16% -62.34% 0.00% 0.00% -131.91% -87.88% 0.00% 0.00%
Return on Assets (ROA)		 0.00% -46.84% -67.16% -62.34% 0.00% 0.00% -133.26% -88.56% 0.00% 0.00%
Return on Common Equity (ROCE)		 -20.57% -48.86% -71.72% -66.85% -96.78% -185.90% -217.33% -349.89% -200.47% -67.31%
Return on Equity Simple (ROE_SIMPLE)		 -20.57% -37.62% -55.59% -56.60% -152.82% -217.75% -178.37% 2,602.54% -95.15% -46.65%
Net Operating Profit after Tax (NOPAT)		 -3.13 -6.66 -18 -26 -34 -35 -44 -41 -31 -39
NOPAT Margin		 0.00% -9,797.94% -7,245.71% -5,892.71% 0.00% 0.00% -3,110.71% -5,805.70% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 8.78% -28.55% -28.17% -23.07% -31.54% -64.86% -80.37% -152.69% -59.15% -17.49%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -68.76% -34.28%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 138.79% 1,706.29% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 5,022.06% 6,276.52% 4,494.39% 0.00% 0.00% 1,345.06% 1,993.57% 0.00% 0.00%
R&D to Revenue		 0.00% 8,097.06% 3,905.26% 3,868.39% 0.00% 0.00% 2,019.75% 2,977.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 14,097.06% 10,451.01% 8,518.16% 0.00% 0.00% 4,405.08% 6,687.57% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -4.47 -9.52 -26 -38 -48 -50 -63 -58 -44 -56
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -3.75 -8.76 -25 -36 -47 -49 -62 -57 -42 -55
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 3.42 8.38 2.93 9.07 26.41 12.30 0.00 15.17 9.32
Price to Tangible Book Value (P/TBV)		 0.00 5.42 10.33 3.34 11.91 37.28 14.78 0.00 16.96 9.66
Price to Revenue (P/Rev)		 0.00 1,272.79 1,561.35 436.45 0.00 0.00 309.48 147.32 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 7.88 43.85 20.01 47.46 241.49 54.67 42.65 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 1,031.68 1,407.23 302.85 0.00 0.00 289.61 154.14 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.01 -29.32 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -28.91 0.00 0.00
Financial Leverage		 -0.26 -0.51 -0.76 -0.87 -0.88 -0.86 -0.83 -0.70 -0.94 -1.02
Leverage Ratio		 1.05 1.04 1.07 1.07 1.16 1.55 1.63 3.95 3.25 1.20
Compound Leverage Factor		 1.05 1.04 1.07 1.07 1.14 1.55 1.65 3.98 3.15 1.15
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.21% 103.53% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.21% 1.44% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 102.09% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 98.79% -3.53% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 -0.01 -1.16 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.46 -0.08 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.15 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 -0.01 -1.62 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.64 -0.12 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.60 0.00 0.00
Altman Z-Score		 0.00 49.96 58.59 24.85 7.72 10.30 4.91 -6.11 17.68 31.98
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 6.06 16.40 17.39 19.42 5.92 2.95 4.30 10.39 6.76 11.88
Quick Ratio		 5.46 16.14 17.20 19.17 5.70 2.70 3.37 10.22 6.61 11.74
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -5.51 -17 -25 -32 -32 -49 -36 -28 -36
Operating Cash Flow to CapEx		 -3,856.98% -12,579.69% -434.61% -8,657.97% -5,622.53% -8,019.27% -12,379.18% -11,723.94% -27,306.61% -29,074.40%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.01 0.01 0.00 0.00 0.03 0.01 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.21 0.17 0.19 0.00 0.00 0.57 0.32 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.85 5.34 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 428.52 68.41 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 -428.52 -68.41 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 10 8.90 7.93 6.75 5.34 2.42 7.51 2.53 -0.01 -3.18
Invested Capital Turnover		 0.00 0.01 0.03 0.06 0.00 0.00 0.29 0.14 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -1.16 -0.98 -1.18 -1.41 -2.92 5.09 -4.98 -2.54 -3.17
Enterprise Value (EV)		 0.00 70 348 135 253 584 411 108 629 953
Market Capitalization		 0.00 87 386 195 279 605 439 103 673 1,071
Book Value per Share		 $1.81 $1.90 $2.81 $3.91 $1.48 $0.90 $1.20 ($0.06) $0.81 $1.87
Tangible Book Value per Share		 $0.48 $1.20 $2.28 $3.43 $1.13 $0.64 $1.00 ($0.20) $0.72 $1.80
Total Capital		 14 25 46 66 31 23 36 64 44 115
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.44 66 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 65 0.00 0.00
Net Debt		 -3.61 -16 -38 -60 -25 -20 -28 4.78 -44 -118
Capital Expenditures (CapEx)		 0.09 0.06 2.55 0.28 0.61 0.44 0.44 0.40 0.12 0.13
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.27 -0.75 -1.80 -2.33 -3.45 -5.72 -0.07 -4.06 -5.75 -8.64
Debt-free Net Working Capital (DFNWC)		 3.34 16 36 57 22 15 29 57 39 109
Net Working Capital (NWC)		 3.34 16 36 57 22 15 28 56 39 109
Net Nonoperating Expense (NNE)		 -0.32 2.86 7.67 11 13 15 20 18 12 14
Net Nonoperating Obligations (NNO)		 -3.61 -16 -38 -60 -25 -20 -28 4.78 -44 -118
Total Depreciation and Amortization (D&A)		 0.72 0.76 1.03 1.17 0.64 1.10 1.16 1.36 1.21 1.18
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -1,100.00% -729.15% -522.20% 0.00% 0.00% -4.73% -579.43% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 23,010.29% 14,683.40% 12,837.22% 0.00% 0.00% 2,013.19% 8,154.71% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 23,010.29% 14,683.40% 12,837.22% 0.00% 0.00% 1,982.44% 8,023.71% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.37) ($0.86) ($1.73) ($2.20) ($2.26) ($2.14) ($2.28) ($1.72) ($0.88) ($0.92)
Adjusted Weighted Average Basic Shares Outstanding		 7.57M 14.14M 16.84M 20.69M 20.83M 26.09M 29.80M 33.94M 48.04M 58.40M
Adjusted Diluted Earnings per Share		 ($0.37) ($0.86) ($1.73) ($2.20) ($2.26) ($2.14) ($2.28) $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 7.57M 14.14M 16.84M 20.69M 20.83M 26.09M 29.80M 37.59M 55.23M 67.27M
Adjusted Basic & Diluted Earnings per Share		 ($0.37) ($0.86) ($1.73) ($2.20) ($2.26) ($2.14) ($2.28) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 7.57M 11.01M 14.75M 17.08M 20.75M 23.25M 27.96M 37.59M 55.23M 67.27M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.13 -6.66 -18 -26 -34 -35 -44 -41 -31 -39
Normalized NOPAT Margin		 0.00% -9,797.94% -7,245.71% -5,892.71% 0.00% 0.00% -3,110.71% -5,805.70% 0.00% 0.00%
Pre Tax Income Margin		 0.00% -13,997.06% -10,351.01% -8,418.16% 0.00% 0.00% -4,489.42% -8,357.86% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.52%

Quarterly Metrics and Ratios for Pulse Biosciences

This table displays calculated financial ratios and metrics derived from Pulse Biosciences' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 -100.00% -101.07% -100.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -26.46% 44.36% 45.36% 27.34% 38.07% -45.43% -11.40% -15.14% -21.98% -63.33%
EBIT Growth		 -26.29% 43.25% 44.64% 27.02% 37.58% -43.32% -11.01% -14.66% -21.36% -61.66%
NOPAT Growth		 -26.29% 43.25% 44.64% 27.02% 37.58% -43.32% -11.01% -14.66% -21.36% -61.66%
Net Income Growth		 -26.31% 40.34% 43.26% 29.19% 41.43% -29.75% -3.43% -14.86% -20.01% -62.45%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 20.36% 37.25% 57.87% 28.23% 1.36% 14.85% -48.86% 8.77% 13.95% -34.83%
Free Cash Flow Firm Growth		 38.15% 92.82% 102.11% 93.26% 9.08% -447.44% -2,091.19% -2,351.07% -5.15% -76.52%
Invested Capital Growth		 -67.22% -66.32% -87.25% -79.66% -17.22% -100.20% 35.46% -55.90% -94.43% -63,420.00%
Revenue Q/Q Growth		 -100.00% 0.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -29.47% 52.45% -10.12% -7.18% -10.36% -11.65% 15.64% -10.78% -16.91% -49.49%
EBIT Q/Q Growth		 -28.62% 51.48% -9.34% -6.95% -10.02% -11.38% 15.30% -10.47% -16.45% -48.38%
NOPAT Q/Q Growth		 -28.62% 51.48% -9.34% -6.95% -10.02% -11.38% 15.30% -10.47% -16.45% -48.38%
Net Income Q/Q Growth		 -28.89% 49.02% -6.57% -1.11% -6.62% -12.94% 15.05% -12.29% -11.39% -52.88%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 17.08% 25.08% 17.51% -40.06% -13.96% 35.33% -44.21% 14.16% -7.49% -1.33%
Free Cash Flow Firm Q/Q Growth		 -88.91% 86.21% 134.37% -175.31% -2,446.76% 16.94% -25.00% 7.30% -9.26% -39.43%
Invested Capital Q/Q Growth		 -75.34% 19.06% -59.09% 69.37% 0.34% -100.28% 28,140.00% -44.86% -87.32% -3,340.82%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.08% 105.17% 102.50% 96.90% 93.90% 95.21% 95.50% 97.07% 92.86% 95.68%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% 0.00% 0.00% -111.89% -135.34% -200.47% -332.14% -100.65% -70.28% -67.31%
Cash Return on Invested Capital (CROIC)		 -951.51% -710.18% -615.12% -496.19% -1,415.25% 0.00% -2,593.84% -2,478.88% -3,479.73% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% 0.00% 0.00% -111.89% -135.34% -200.47% -332.14% -100.65% -70.28% -67.31%
Return on Equity Simple (ROE_SIMPLE)		 -1,045.79% 0.00% 478.37% -77.60% -75.70% 0.00% -117.25% -163.22% -58.30% 0.00%
Net Operating Profit after Tax (NOPAT)		 -13 -6.12 -6.69 -7.16 -7.88 -8.77 -7.43 -8.21 -9.56 -14
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -24.11% -26.29% -638.77% -7.48% -9.88% -15.96% -23.35% -7.48% -4.82% -6.41%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -19.78% - - - -12.35%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -18 -8.75 -9.56 -10 -11 -13 -11 -12 -14 -20
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -18 -8.41 -9.26 -9.93 -11 -12 -10 -11 -13 -20
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 13.80 0.00 0.00 4.47 4.24 15.17 13.26 22.91 13.59 9.32
Price to Tangible Book Value (P/TBV)		 125.39 0.00 0.00 4.88 4.68 16.96 15.14 27.31 14.34 9.66
Price to Revenue (P/Rev)		 54.98 147.32 493.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 38.27 42.65 133.35 120.88 97.14 0.00 318.21 765.56 10,163.25 0.00
Enterprise Value to Revenue (EV/Rev)		 52.37 154.14 539.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 10.52 -29.32 -6.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 10.50 -28.91 -6.09 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.84 -0.70 -0.10 -0.88 -0.93 -0.94 -0.90 -0.97 -0.99 -1.02
Leverage Ratio		 2.89 3.95 10.84 1.37 2.63 3.25 4.66 1.32 1.21 1.20
Compound Leverage Factor		 2.89 4.16 11.11 1.33 2.47 3.10 4.45 1.28 1.12 1.15
Debt to Total Capital		 91.32% 103.53% 119.35% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.14% 1.44% 1.45% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 91.18% 102.09% 117.90% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 8.68% -3.53% -19.35% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -1.03 -1.16 -1.34 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.06 -0.08 -0.24 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -1.03 -1.15 -1.33 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -1.44 -1.62 -1.87 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.09 -0.12 -0.33 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -1.43 -1.60 -1.84 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -3.72 -4.02 -4.76 5.92 3.00 19.41 12.57 14.81 41.24 32.87
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 10.17 10.39 7.86 10.68 9.50 6.76 7.06 4.57 11.93 11.88
Quick Ratio		 9.88 10.22 7.74 10.47 9.28 6.61 6.87 4.39 11.72 11.74
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -8.26 -1.14 0.39 -0.29 -7.51 -6.24 -7.80 -7.23 -7.90 -11
Operating Cash Flow to CapEx		 -17,148.39% -19,426.83% -16,846.15% -57,512.50% -45,595.65% -15,772.09% -195,600.00% -28,948.28% -23,747.37% -17,252.83%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.02 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 40.34 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 4.73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.66 0.32 0.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 5.03 5.34 3.91 5.18 0.75 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 9.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 77.20 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 72.55 68.41 93.38 70.47 485.44 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 13.70 -68.41 -93.38 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 2.13 2.53 1.04 1.75 1.76 -0.01 1.40 0.77 0.10 -3.18
Invested Capital Turnover		 0.36 0.14 0.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -4.36 -4.98 -7.09 -6.86 -0.37 -2.54 0.37 -0.98 -1.66 -3.17
Enterprise Value (EV)		 81 108 138 212 171 629 446 592 996 953
Market Capitalization		 85 103 126 271 221 673 481 618 1,075 1,071
Book Value per Share		 $0.17 ($0.06) ($0.29) $1.61 $0.95 $0.81 $0.66 $0.49 $1.29 $1.87
Tangible Book Value per Share		 $0.02 ($0.20) ($0.43) $1.47 $0.86 $0.72 $0.58 $0.41 $1.22 $1.80
Total Capital		 71 64 55 61 52 44 36 27 79 115
Total Debt		 65 66 66 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 65 65 65 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -4.06 4.78 12 -59 -50 -44 -35 -26 -79 -118
Capital Expenditures (CapEx)		 0.06 0.04 0.04 0.02 0.02 0.04 0.01 0.03 0.04 0.05
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.90 -4.06 -5.34 -4.40 -4.20 -5.75 -4.12 -4.92 -5.36 -8.64
Debt-free Net Working Capital (DFNWC)		 64 57 49 54 46 39 31 21 74 109
Net Working Capital (NWC)		 64 56 48 54 46 39 31 21 74 109
Net Nonoperating Expense (NNE)		 5.42 3.08 3.11 2.75 2.69 3.16 2.71 3.17 3.12 5.20
Net Nonoperating Obligations (NNO)		 -4.06 4.78 12 -59 -50 -44 -35 -26 -79 -118
Total Depreciation and Amortization (D&A)		 0.34 0.34 0.30 0.30 0.30 0.30 0.30 0.30 0.29 0.29
Debt-free, Cash-free Net Working Capital to Revenue		 -315.58% -579.43% -2,086.33% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 4,137.86% 8,154.71% 19,045.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 4,131.55% 8,023.71% 18,732.81% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.49) ($0.21) ($0.26) ($0.22) ($0.19) ($0.18) ($0.18) ($0.20) ($0.21) ($0.33)
Adjusted Weighted Average Basic Shares Outstanding		 37.16M 33.94M 37.39M 44.51M 54.92M 49.74M 55.17M 57.18M 61.07M 58.40M
Adjusted Diluted Earnings per Share		 ($0.49) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 37.16M 37.59M 37.64M 54.90M 54.99M 55.23M 55.23M 61.29M 61.52M 67.27M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 37.23M 37.59M 37.64M 54.90M 54.99M 55.23M 55.23M 61.29M 61.52M 67.27M
Normalized Net Operating Profit after Tax (NOPAT)		 -13 -6.12 -6.69 -7.16 -7.88 -8.77 -7.43 -8.21 -9.56 -14
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.52%

Frequently Asked Questions About Pulse Biosciences' Financials

When does Pulse Biosciences's fiscal year end?

According to the most recent income statement we have on file, Pulse Biosciences' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Pulse Biosciences' net income changed over the last 9 years?

Pulse Biosciences' net income appears to be on an upward trend, with a most recent value of -$53.59 million in 2024, rising from -$2.81 million in 2015. The previous period was -$42.21 million in 2023.

What is Pulse Biosciences's operating income?
Pulse Biosciences's total operating income in 2024 was -$56.26 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $56.26 million
How has Pulse Biosciences revenue changed over the last 9 years?

Over the last 9 years, Pulse Biosciences' total revenue changed from $0.00 in 2015 to $0.00 in 2024, a change of 0.0%.

How much debt does Pulse Biosciences have?

Pulse Biosciences' total liabilities were at $17.60 million at the end of 2024, a 19.0% increase from 2023, and a 2,566.4% increase since 2015.

How much cash does Pulse Biosciences have?

In the past 9 years, Pulse Biosciences' cash and equivalents has ranged from $2.09 million in 2016 to $118.04 million in 2024, and is currently $118.04 million as of their latest financial filing in 2024.

How has Pulse Biosciences' book value per share changed over the last 9 years?

Over the last 9 years, Pulse Biosciences' book value per share changed from 1.81 in 2015 to 1.87 in 2024, a change of 3.4%.


Related Companies

This page (NASDAQ:PLSE) was last updated on 5/5/2025 by MarketBeat.com Staff
From Our Partners
Elon’s Terrifying Warning Forces Trump To Take Action
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...
American Hartford Gold | Sponsored
Elon Reveals Why There Soon Won’t Be Any Money For Social Security
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...
Colonial Metals | Sponsored
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...
Altimetry | Sponsored
Trump’s Bitcoin Reserve is No Accident…
Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...
Crypto 101 Media | Sponsored
Shocking AI play that’s beats Nvidia by a country mile
You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...
Timothy Sykes | Sponsored
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
Man who predicted $100K Bitcoin sees a huge run coming for another coin …
Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...
Weiss Ratings | Sponsored
Musk's warning signal: Prepare before the cascade begins
When Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...
InvestorPlace | Sponsored